Tvardi Therapeutics
TVRD
73 hedge funds and large institutions have $102M invested in Tvardi Therapeutics in 2025 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 6 closing their positions.
2,253% more call options, than puts
Call options by funds: $1.72M | Put options by funds: $73K
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
283% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 6
128% more capital invested
Capital invested by funds: $44.9M → $102M (+$57.3M)
30% more funds holding
Funds holding: 56 → 73 (+17)
7.23% more ownership
Funds ownership: 20.78% → 28% (+7.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$4.75M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$2.35M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.34M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.85M |
| 5 |
BlackRock
New York
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$583K |
| 2 |
HT
Headlands Technologies
Chicago,
Illinois
|
-$80K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$49.1K |
| 4 |
Morgan Stanley
New York
|
-$31.5K |
| 5 |
Citigroup
New York
|
-$30.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KWM
76
Kiker Wealth Management
Jasper,
Georgia
| – | -$303 | -13 | Closed |
|
|
TCOT
77
Trust Company of Toledo
Holland,
Ohio
| – | -$210 | -9 | Closed |
|
|
CIAM
78
Caitong International Asset Management
Hong Kong
| – | -$23 | -1 | Closed |
|
79
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$142 | +5 | New |
|
TVRD Hedge Fund Activity: Q3 2025 in Review
73 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2025, worth a combined $102M — up 128% from $44.9M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new TVRD positions and 6 closed out — a net gain of 17 holders — while 23 added to existing stakes and 6 trimmed.
The largest buyer was Vestal Point Capital, opening a new position worth an estimated $4.75M. The largest seller was Marshall Wace, exiting entirely with an estimated $583K sold.
- 73 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2025, up from 56 in Q2 2025.
- Funds reported $102M of Tvardi Therapeutics stock for Q3 2025, up 128% quarter-over-quarter.
- 23 funds opened new Tvardi Therapeutics positions in Q3 2025 and 6 closed out, a net change of +17 holders.
- The largest Tvardi Therapeutics buyer in Q3 2025 was Vestal Point Capital, an estimated $4.75M added.
- The largest Tvardi Therapeutics seller in Q3 2025 was Marshall Wace, an estimated $583K sold.
Based on aggregated 13F filings for Q3 2025.